AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34970741
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the leg region
Trial: 34970741
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the abdominal region
Trial: 34970741
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the arm region
Trial: 34970741
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) injection after coolant spray application in the abdominal and arm regions
Trial: 33518395
Drug: Inpatient single-agent
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient single-agent regimen (Group A): cefazolin sodium 1g preoperatively and every eight hours for 48 hours postoperatively
Trial: 33518395
Drug: Extended dual-agent
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dual-agent regimen (Group B): cefazolin sodium 1g preoperatively and every eight hours for 48 hours postoperatively, followed by oral amoxicillin for three days
Trial: 36259684
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (weeks 6-16)
Trial: 33588408
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) or other interventions for sleep apnea (exact dosage and duration not specified)
Trial: 33118908
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) delivered by trained lay health workers; 8 sessions
Trial: 34052065
Drug: 20 µg recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg recombinant hepatitis B vaccine (IM20 group)
Trial: 34052065
Drug: 60 µg recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg recombinant hepatitis B vaccine (IM60 group)
Trial: 35964661
Drug: Delivery room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery room insertion of etonogestrel implant (0 to 2 hours postdelivery)
Trial: 35964661
Drug: Delayed insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed insertion of etonogestrel implant (24 to 48 hours postdelivery)
Trial: 35964661
Drug: Delivery room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery room insertion of etonogestrel implant
Trial: 35964661
Drug: Delayed insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed insertion of etonogestrel implant
Trial: 33544985
Drug: Conventional (chemical)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional (chemical) treatment of 40% H2O2
Trial: 34387114
Drug: Olanzapine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (low doses)
Trial: 34387114
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg or equivalent)
Trial: 33081828
Drug: Tocilizumab (1-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (1-h intravenous infusion)
Trial: 35364216
Drug: CTP-543 4
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: CTP-543 4 mg twice daily
Trial: 35364216
Drug: CTP-543 8
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: CTP-543 8 mg twice daily
Trial: 35364216
Drug: CTP-543 12
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: CTP-543 12 mg twice daily
Trial: 35010938
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical nutrition therapy (MNT) plus metformin (850 mg twice/day)
Trial: 35010938
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical nutrition therapy (MNT) without metformin
Trial: 33186771
Drug: Uterine Toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine Toxin Botulinic injections (BTX) under hysteroscopy (200 IU of Incobotulinum-toxin A)
Trial: 33186771
Drug: Uterine Toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine Toxin Botulinic injections (BTX) under hysteroscopy
Trial: 32379668
Drug: Benson relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson relaxation technique (BRT), performed twice daily for 20 min over one month
Trial: 35034428
Drug: Insulin-GLP-1 RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-GLP-1 RA relay group (mean 16.8 ± 11.4 IU/day for 12 weeks, then liraglutide for 12 weeks)
Trial: 35034428
Drug: GLP-1 RA
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLP-1 RA first group (liraglutide 0.9 mg for 24 weeks)
Trial: 35820444
Drug: Accelerated systemic
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated systemic fibrinolytic therapy (FT) with 100 mg t-PA in 2 hours
Trial: 35820444
Drug: Full-dose systemic
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose systemic fibrinolysis
Trial: 33136819
Drug: Peer change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer change agent Type I network intervention with opinion leader workshop and telephonic booster sessions
Trial: 33136819
Drug: Peer change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer change agent Type I network intervention
Trial: 36164334
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline nasal spray)
Trial: 34242256
Drug: General health
RxNorm normalized name: Walgreens Men-General Health Multivitamin Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General health messages daily for two months
Trial: 34114691
Drug: AUC-targeted therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUC-targeted therapeutic drug monitoring (TDM)
Trial: 34569167
Drug: Risedronate (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (150 mg once monthly)
Trial: 32719133
Drug: Experiments involving
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiments involving randomization of policies or treatments
Trial: 32719133
Drug: Approval of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approval of policies or treatments
Trial: 32744395
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U300 (IGlarU300)
Trial: 35124626
Drug: Motion style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motion style acupuncture therapy (MSAT) combined with conventional acupuncture therapy (CAT)
Trial: 35124626
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture therapy (CAT)
Trial: 35752582
Drug: Gefapixant 15
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 15 mg BID
Trial: 36879087
Drug: Gefapixant 45
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 45 mg BID
Trial: 32272623
Drug: Solution-focused group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused group counseling intervention for five weeks
Trial: 33960181
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor stimulation (20 minutes before conventional therapy)
Trial: 33960181
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (90 minutes, five times/week for four months)
Trial: 33960181
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor stimulation
Trial: 32807209
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg orally daily for 14 days
Trial: 33888314
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (15 mg/kg, maximum 1 g)
Trial: 33340316
Drug: Baloxavir (40/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baloxavir (40/80 mg single dose based on weight)
Trial: 36073362
Drug: Tribulus terrestris
RxNorm normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribulus terrestris L.
Trial: 32227772
Drug: Clysis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clysis therapy using glycerin enemas or lactulose oral solution (Control)
Trial: 33290437
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection (n = 20)
Trial: 36286979
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg 1 time per day + Alfasoxx 1 sachet qid (intervention group)
Trial: 36286979
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg 1 time per day (control group)
Trial: 36286979
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (intervention group)
Trial: 36286979
Drug: Standard PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PPI monotherapy (control group)
Trial: 33170378
Drug: l-Carnosine (10–15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnosine (10–15 mg/kg in 2 divided doses) plus standard care (occupational and speech therapy)
Trial: 33170378
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (occupational and speech therapy)
Trial: 36446797
Drug: Neurorehabilitation protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurorehabilitation protocol integrating assisted locomotion with a noninvasive brain-machine interface (L + BMI)
Trial: 36446797
Drug: L +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L + BMI group
Trial: 33964828
Drug: Combined eradication
RxNorm normalized name: Combinations for eradication of Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined eradication and prokinetic therapy (itoprid hydrochloride 50 mg three times a day)
Trial: 33964828
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy only
Trial: 32227108
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy clinicians' involvement in research
Trial: 35978377
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) intervention for 72 weeks
Trial: 32093652
Drug: Ketotifen Fumarate
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen Fumarate (KF) 2 mg or 5 mg
Trial: 34312798
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide fumarate (TAF) 25 mg/day
Trial: 32816829
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (same programme starting 2 months later)
Trial: 34997825
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g
Trial: 34750392
Drug: Adjuvant gefitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gefitinib or chemotherapy based on genomic profiling
Trial: 37245533
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (20 IU, twice/day) with dulaglutide (1.5 mg/week)
Trial: 37245533
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo with dulaglutide (1.5 mg/week)
Trial: 37245533
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (20 IU, twice/day) with placebo
Trial: 37245533
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo with placebo
Trial: 33581015
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy (MT) group
Trial: 33581015
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (IT) group
Trial: 33392802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received traditional surgical therapy with primary closure of the surgical area.
Trial: 33032612
Drug: LUS or
RxNorm normalized name: Aspergillus oryzae
DrugBank: Aspergillus oryzae (DB10448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUS or CXR not suggestive of BN and PCT > 1 ng/mL
Trial: 33032612
Drug: LUS or
RxNorm normalized name: Aspergillus oryzae
DrugBank: Aspergillus oryzae (DB10448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUS or CXR not suggestive of BN and PCT < 1 ng/mL
Trial: 35254932
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of peer comparison and individual audit feedback
Trial: 33267837
Drug: Oral clonazepam
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonazepam (0.05 mg/Kg)
Trial: 33267837
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam (0.05 mg/Kg)
Trial: 36215079
Drug: Transcatheter PFO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter PFO closure plus antithrombotic therapy
Trial: 36215079
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy alone
Trial: 34519832
Drug: calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium and vitamin D supplements (CaD)
Trial: 33162978
Drug: GAD‐alum injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD‐alum injection (4 μg) into lymph nodes + oral Vitamin D (2000 U/d)
Trial: 32828678
Drug: Amoxicillin alone
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin alone (70 mg/kg) for five days
Trial: 32828678
Drug: Amoxicillin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (70 mg/kg) plus clarithromycin (15 mg/kg) for the initial three days
Trial: 34358811
Drug: One-view craniocaudal
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-view craniocaudal (CC) DM-DBT
Trial: 34358811
Drug: CC DM-DBT
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CC DM-DBT view
Trial: 33022713
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg/d)
Trial: 33515998
Drug: Phytase supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytase supplementation (1 000 U/kg diet) with 1.0, 1.5, or 2.0 g/kg NPP
Trial: 33515998
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (phytase-absent) with 2.0, 2.5, or 3.0 g/kg NPP
Trial: 32510734
Drug: Single 1.2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1.2-g dose of oral azithromycin
Trial: 32510734
Drug: Initial adult
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial adult dose of 500 mg followed by 250 mg per day for 4 days (total cumulative dose of 1.5 g)
Trial: 32510734
Drug: For children
RxNorm normalized name: Nurofen For Children
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For children aged 5 to 18 years, 10 mg/kg on the first day followed by 5 mg/kg for 4 days
Trial: 34117375
Drug: Direct supplementation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct supplementation with Urolithin A (500 mg)
Trial: 32167978
Drug: S-ketamine 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine 0.12 mg/kg/h
Trial: 32167978
Drug: S-ketamine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine 0.6 mg/kg/h
Trial: 33326257
Drug: Capivasertib (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib (320 mg twice daily, 4 days on/3 days off)
Trial: 35759637
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (1 g)
Trial: 35759637
Drug: Subcutaneous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous tranexamic acid (1 g)
Trial: 33921829
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum CJLP55 supplement
Trial: 33038271
Drug: 1.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/kg alcohol dose
Trial: 33975304
Drug: Social Nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Nutrition Program (additional 27 g of protein/day and social network intervention)
Trial: 32672800
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg, plus verteporfin photodynamic therapy (vPDT)
Trial: 32672800
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg, plus sham PDT
Trial: 32349041
Drug: L reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L reuteri DSM 17938
Trial: 32349041
Drug: L rhamnosus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L rhamnosus 19070‐2
Trial: 32349041
Drug: L reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L reuteri DSM 12246
Trial: 32349041
Drug: L helveticus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L helveticus R0052
Trial: 32349041
Drug: L rhamnosus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L rhamnosus R0011
Trial: 32071176
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo treatment with treatment rationale
Trial: 32071176
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo treatment without treatment rationale
Trial: 34731434
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection combined with CSEA plus PCEA (AICP group, n=168)
Trial: 34080789
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration via intravenous and dorsal pancreatic arterial routes
Trial: 34080789
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration